22 May 2013
Keywords: Idenix, Hepatitis C program, Novartis, FDA, Clinical hold
Article | 08 September 2010
Shares in US drug developer Idenix Pharmaceuticals (Nasdaq: IDIX) plunged 55% in pre-marketing trading yesterday after the company said it had ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 September 2010
7 September 2010
21 May 2013
© 2013 thepharmaletter.com